Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC)

The LBMCC is a privately funded, non-profit cancer research laboratory located in Luxembourg City. Our location in the heart of Europe lets us collaborate with European universities in France, Germany and Belgium. These, along with our transatlantic collaborations, allow us to integrate an active and productive scientific network.

Research projects in our lab are co-financed by the association "Recherches Scientifiques Luxembourg", by the foundation "Fondation de Recherche Cancer et Sang" and by Televie. We also receive financial support from "Een Haerz fir Kriibskrank Kanner" and the Ministry of Research.

The research facility covers 589 m2, spread over 15 rooms, at Kirchberg Hospital and is equipped with all the necessary equipment for 25 biochemists. Our staff is currently composed of about 20 people and will be continuously growing over the next few years.
The lab mainly focuses on basic and applied research linking inflammation, cancer and leukemia. This involves, among other things, a better understanding of the molecular mechanisms behind the development of resistance to chemotherapeutic agents, the underlying mechanisms of inflammation signaling, and the important hunt for novel therapeutic approaches based on compounds of natural origins. The natural products are screened and their effect on these mechanisms is examined.

Another group focuses on differentiation therapy. This approach is based on the concept that cancer cells are more immature (or less differentiated). These cells normally show a higher proliferation rate compared to their healthy counterparts. Differentiation therapy thus aims to return these cells to a more mature, less proliferative differentiation state. Such an approach may help to slow down cancer progression and additionally make cancer cells more sensitive to cancer chemotherapeutics.

A further research group performs epigenetic research in order to understand the underlying mechanisms involved in—and potentially find new biomarkers for—early cancer detection. They also screen various natural products to see which can modulate epigenetic modifications for cancer prevention, and how.